Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company ...

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

Sarilumab treatment with a rapid glucocorticoid taper in relapsing polymyalgia rheumatica shows greater improvements in ...

A federal judge on Thursday declined to block the bankruptcy sale of genetic testing company 23andMe to its co-founder Anne ...

Interleukin-2 (IL-2) inhibitors are immunosuppressive agents that block the activity of IL-2, a cytokine involved in the activation and proliferation of T cells. The growing prevalence of autoimmune ...

The Paroxysmal Nocturnal Hemoglobinuria treatment market is experiencing significant expansion, driven by increasing disease awareness, rising preval ...

This was the stock's third consecutive day of gains.

RFK Jr. cancels U.S. Preventive Services Task Force meeting; the Department of Health and Human Services backtracked on its claim that it would release ethics forms for new members of the Advisory ...

The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public ...

Utah families who used 23andMe's genetic testing services face unique privacy risks as the biotech company enters bankruptcy proceedings and prepares for sale t ...

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" ...